Oxford Medical Products has announced positive three-month clinical trial results for Sirona, a weight-loss treatment aimed at overweight individuals and those transitioning off GLP-1 medications. The ...

A weight loss drug that expands in the stomach to create a sustained feeling of fullness has shown promising three-month Phase 2 clinical trial results. The treatment, known as Sirona, is taken as a ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...

Weight loss in the trial on CagriSema was 13.7% after 68 weeks, when including even the participants that dropped out of the trial. Weight loss on CagriSema was 15.7% when including only those ...

Over 30% of patients on pemvidutide 2.4 mg lost ≥ 20% body weight in the Phase 2 MOMENTUM trial. Pemvidutide cut liver fat by 76.4% at 24 weeks in a Phase 1b MASLD study, compared to 14% for ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...